Latest news with #ORIC
Business Recorder
39 minutes ago
- Business
- Business Recorder
Delegation of South Korea visits UAF
FAISALABAD: A South Korean delegation visited the University of Agriculture Faisalabad (UAF) and called on deans and directors to discuss the areas of mutual concerns. On the directives of UAF Vice Chancellor Prof Dr Zulfiqar Ali the meeting was held at the Office of Research, Innovation and Commercialization (ORIC). The delegation included AJOU Motor College Dean International Cooperation Centre and Department Prof Dr Kwonse Kim and Director International Cooperation Office Kim Tae Hyoung, OAKS CAF Chairman Seo Young Oak, CEO Lee Jae Ho and Company's Secretary Dr Abdul Ghaffar Director ORIC Prof Dr Muhammad Imran Arshad highlighted UAF's legacy as one of the leading agricultural institutions in Asia, known for its tangible research and strong community engagement. He stresses upon the collaborations in agriculture and food security. He said that UAF sub-campuses across the Punjab, various research centers and specialized departments contributing to multidisciplinary education and development. Director External Linkages Dr Tehseen Azhar said that said that partnership with South Korea will open new horizons for joint research and global academic exposure for students and faculty as well. Prof Dr Kwonse Kim said that AJOU Motor College focuses on practical learning, technical innovation and student-centered facilities. He said we equip students with hands-on experience in the automotive sector. He said that AJOU has strong interest in developing academic linkages with UAF. He offered a proposed student exchange program, ensuring mutual learning and cultural exchange. Dr Abdul Ghaffar said that through exchange program and scholarships, AJOU is offering the students an opportunity to have international exposure and cultural understanding. Dean Faculty of Agriculture Engineering and Technology Prof Dr Anjum Munir said that advancements in farm machinery and power systems being developed at UAF are playing vital role in advancing agriculture and enhancing the efficiency and productivity. Copyright Business Recorder, 2025
Business Recorder
12-07-2025
- Business
- Business Recorder
VC UAF emphasises industry-academia linkages
FAISALABAD: Knowledge of economy and strengthened industry-academia linkages are prerequisite for sustainable economic development and poverty alleviation. For which, a comprehensive strategy is being mapped out to commercialize the research work so that the farming community and general public can benefit. It would also create employment opportunities, said University of Agriculture Faisalabad Vice Chancellor Prof Dr Zulfiqar Ali. Chairing a strategic review meeting in ORIC's conference room, joined by Director Research Prof Dr Imran Arshad, Prof. Dr. Zahid Abbas, the Vice Chancellor outlined an ambitious roadmap to enhance operational efficiency and accelerate research commercialization. Prof Dr Zulfiqar Ali underscored the pivotal role of the Office of Research, Innovation and Commercialization (ORIC) as a facilitator and engine for professional advancement at the varsity. He emphasized Director ORIC for strengthening human capital, including new faculty members, to ensure competence in research management, intellectual property rights, patenting, commercialization, and transparent financial workflows. He directed setting up a facilitation desk at ORIC to provide necessary guidance to PIs and ensure completion of all prerequisites. Recalling his position as Director ORIC at Muhammad Nawaz Sharif University of Agriculture Multan, he said that due to establishment of facilitation desk there, faculty members were provided with all necessary guidance and facilities. He underscored the need for examining and analyzing at least two models of commercialization from leading international and local universities. He asked ORIC to circulate instructions to the faculty members for inclusion of social scientists as co-principal investigators in all research proposals to enhance societal relevance and impact creation. Copyright Business Recorder, 2025
BBC News
03-07-2025
- Business
- BBC News
Thames Water sewage treatment works 'cannot handle' demand
More than half of Thames Water's sewage treatment works are unable to deal with the volume of sewage they receive, campaigners have conducted by the Oxford Rivers Improvement Campaign (ORIC) identified 181 treatment works that could not handle the amount of sewage said in some cases, such as Hanwell and Bourton-on-the-Water, facilities were treating less than half of the sewage Water said it was putting in a "record amount of investment" to address "ageing infrastructure" and meet the demands of population growth and climate change. ORIC said 94 treatment works had between 80% to 100% of the necessary treatment capacity, 70 were between 60% and 80%, and an "alarming" 17 sites functioned at less than 60%."A lack of treatment capacity leads to untreated sewage discharges/storm overflows happening more frequently," it added."Most of the worst-performing works are found outside of London in headwater streams and tributaries of the River Thames, where raw or partially treated sewage is likely to be more harmful to the river ecosystem, as small waterbodies cannot dilute pollutants effectively."The findings can be viewed on the Oxford Rivers Project Portal's interactive map. John Bryden, head of improving rivers at environmental charity Thames21, and regional development manager at The Rivers Trust, said: "Thames Water's underperforming sewage works need to be upgraded to meet modern regulatory requirements."Where housing growth is planned, upgrades to sewage works are needed before the development is constructed."ORIC co-founder Mark Hull said there was a "rising tide of raw sewage discharges" into the Thames, describing it as "astonishing" how some treatment works were operating without sufficient capacity. Thames Water, which has 351 sewage treatment works, was hit with a record £122.7m fine by regulator Ofwat for repeatedly breaching rules over sewage spills and making payouts to shareholders when in dire financial Fayers, the company's waste and bioresources director, said: "We believe that all storm discharges to the environment, even when permitted, are unacceptable, however, it's important to remember that the system was historically designed in this way to prevent sewage backing up into homes. "This is an issue that will take many years and significant investment to resolve and is at the heart of our storm overflow action plan."Transparency is at the heart of what we do, and we were the first water company to publish a real time data map on our website showing all storm overflows, before it became legal requirement to do so." You can follow BBC Oxfordshire on Facebook, X (Twitter), or Instagram.
Yahoo
06-06-2025
- Business
- Yahoo
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the 'Grant Date'), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC's common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36th) of the remaining shares vesting each one-month period thereafter. One-third (1/3rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan. The inducement grants were approved by ORIC's Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4). About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to and follow us on X or LinkedIn. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC's product candidates; the potential advantages of ORIC's product candidates; and plans underlying ORIC's clinical trials and development. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'intends,' 'will,' 'goal,' 'potential' and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC's ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC's plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC's product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC's operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC's license and collaboration agreements; the potential market for our product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC's ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC's reliance on third parties, including contract manufacturers and contract research organizations; ORIC's ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in ORIC's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the 'SEC') on May 5, 2025, and ORIC's future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Contact:Dominic Piscitelli, Chief Financial info@ sesión para acceder a tu cartera de valores
Yahoo
30-05-2025
- Business
- Yahoo
ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) has unveiled promising early results from its Phase 1b trial of ORIC-944, a novel PRC2 inhibitor, in combination with androgen receptor inhibitors for metastatic castration-resistant prostate cancer (mCRPC). The study reported broad and deep prostate-specific antigen (PSA) responses, with a 59% PSA50 response rate (47% confirmed, plus one pending) and a 24% confirmed PSA90 response rate. These robust responses were seen across all dose levels and with both apalutamide and darolutamide combinations. Most patients remain on therapy, with several approaching one year or more of treatment. A scientist examining cells in a lab, representing the company's dedication to developing specialty pharmaceuticals. Safety data were also encouraging: the vast majority of adverse events were mild or moderate (Grade 1 or 2), primarily gastrointestinal, supporting long-term dosing suitability. Only one patient experienced a Grade 3 event, and there were no severe (Grade 4 or 5) treatment-related adverse events. ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) plans to advance two recommended Phase 2 doses for each combination into further study, with a global Phase 3 trial set to begin in the first half of 2026. To support these efforts, ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced a $125 million private placement financing led by top healthcare investors, extending its cash runway into the second half of 2027 and through the anticipated Phase 3 trial readout. While we acknowledge the potential of ORIC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORIC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
